Second part of results from new AndoSan™ IBD study published in July 2016

August
2016

During 2015, a clinical trial into the use of AndoSan™ as add-on therapy for patients with chronic inflammatory bowel disease (IBD) was conducted at Oslo University Hospital. With a total of hundred patients included, this was a large clinical trial for Norwegian conditions.

The trial was split into two groups of fifty patients each. The groups were studied separately, the first fifty patients were being treated for light to moderate ulcerative colitis and the other fifty patients were treated for light to moderate Crohn’s disease. The study of patients with ulcerative colitis was published in March this year and showed very good results. The researchers [1] concluded that beneficiary effects on symptoms, fatigue and health related quality of life from AndoSan™ consumption were demonstrated in this peer reviewed study, supporting use of AndoSan™ as a supplement to conventional medication for patients with mild to moderate symptoms from ulcerative colitis.

This article was followed up in July with the publication of results from patients with Crohn’s disease [2]. Although specific results in patients with Crohn’s disease were not as spectacular as in patients with ulcerative colitis, the authors found interesting outcome in the AndoSan™ group. This was not surprising since previous studies [3] have also shown the best results for patients with ulcerative colitis.

The study found clear clinical tendencies to improvements in the AndoSan™ group  compared  with  placebo.  Even though the difference was not found to be statistically significant, the researchers concluded that Crohn’s patients with mild to moderate symptoms may have beneficiary effects of AndoSan™ as a safe supplement in addition to conventional medication.

The researchers are currently undertaking a statistical review of the analysis of blood samples collected during the clinical part of the study. A third publication is planned late in 2016 or early in 2017.

The study is largely funded by the Oslo University Hospital and will form the foundation for a PhD thesis.

References:

  1. Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E (2016) Effect of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™, on Symptoms, Fatigue and Quality of Life in Patients with Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study. PLoS ONE 11(3): e0150191. doi:10.1371/journal.pone.0150191
  2. Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E (2016) Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan, on Symptoms, Fatigue  and  Quality  of  Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study. PLoS ONE 11(7): e0159288. doi:10.1371/journal.pone.0159288
  3. Førland DT, Johnson E, Saetre L, Lyberg T, Lygren I, Hetland G (2011) Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn’s disease. Scand J Immunol. 2011 Jan; 73(1): 66-75. doi: 10.1111/j.1365-3083.2010.02477.x.